Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Asset Writedowns and Impairment (2024)

Seres Therapeutics' Asset Writedowns and Impairment history spans 1 years, with the latest figure at $3.3 million for Q1 2024.

  • For Q1 2024, Asset Writedowns and Impairment changed N/A year-over-year to $3.3 million; the TTM value through Dec 2024 reached $3.3 million, changed N/A, while the annual FY2024 figure was $3.3 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q1 2024 was $3.3 million at Seres Therapeutics.
  • Across five years, Asset Writedowns and Impairment topped out at $3.3 million in Q1 2024 and bottomed at $3.3 million in Q1 2024.